Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abacavir
Drug ID BADD_D00008
Description Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
Indications and Usage For the treatment of HIV-1 infection, in combination with other antiretroviral agents.
Marketing Status Prescription
ATC Code J05AF06
DrugBank ID DB01048
KEGG ID D07057
MeSH ID C106538
PubChem ID 441300
TTD Drug ID D0A4IJ
NDC Product Code 50268-049; 55111-920; 65862-073; 0121-0897; 72865-167; 0904-6874; 70518-1274; 31722-562; 31722-557; 69097-514; 64380-717
Synonyms abacavir | 1592U89 | abacavir sulfate | Ziagen | (1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol | abacavir succinate
Chemical Information
Molecular Formula C14H18N6O
CAS Registry Number 136470-78-5
SMILES C1CC1NC2=C3C(=NC(=N2)N)N(C=N3)C4CC(C=C4)CO
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic enzyme increased13.03.01.0190.028334%Not Available
Inflammation08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Ill-defined disorder08.01.03.049--Not Available
Autoimmune disorder10.04.04.003--
Respiratory tract infection viral11.05.04.003; 22.07.07.002--Not Available
Lipohypertrophy14.08.04.009; 23.07.01.005--
Respiratory tract infection11.01.08.017; 22.07.07.001--Not Available
Hyperamylasaemia14.11.01.003--Not Available
Breath sounds abnormal13.15.01.008--Not Available
AIDS dementia complex10.03.03.005; 11.05.17.008; 17.03.01.005; 19.20.02.004--Not Available
Immune reconstitution inflammatory syndrome08.06.02.014; 10.02.01.0430.018890%Not Available
Oropharyngeal discomfort07.05.05.008; 22.02.05.027--Not Available
Oropharyngeal pain07.05.05.004; 22.02.05.022--
Sensitisation08.01.05.009; 10.02.01.012--Not Available
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 23.03.05.0050.094448%Not Available
Liver function test increased13.03.01.044--Not Available
Persistent depressive disorder19.15.01.006--Not Available
Viral mutation identified13.08.03.0360.122782%Not Available
Virologic failure08.06.01.034; 11.01.08.0620.122782%Not Available
The 5th Page    First    Pre   5    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene